TB treatment and care
To cure TB and reduce disease transmission, patients should be placed on effective treatment soon after diagnosis. Treatment should be provided to all who need it regardless of age, sex, gender or type of TB disease, bacteriological status, co-morbidities or legal status of the patient. In most circumstances, community-based treatment adherence support may lead to more favourable treatment outcomes. Ensuring all TB patients have access to free-of-charge life-saving treatment is fundamental to minimizing disease and deaths due to TB.
53 million lives saved since 2000 through effective diagnosis and TB treatmentGlobal TB report 2017 facts
83%of people newly diagnosed with TB successfully completed treatment in 2016Global TB report 2017
News and events
The 20th WHO Expert Committee meeting on the selection and use of essential medicines has recommended the inclusion of five medicines (bedaquiline, delamanid, linezolid, rifapentine and terizidone) in the anti- tuberculosis medicines section of the WHO Model List of Essential Medicines.
- Guidelines for treatment of drug-susceptible tuberculosis and patient care (2017 update)
- Policy Implementation Package for new TB drug introduction
- WHO interim guidance on the use of delamanid in the treatment of MDR-TB
- The use of bedaquiline in the treatment of multidrug-resistant tuberculosis
- Nutritional care and support for patients with tuberculosis